Zhongsheng Pharma subsidiary wins drug approval

Guangdong Zhongsheng Pharmaceutical announced its wholly-owned subsidiary has received approval from the National Medical Products Administration for aluminum clofibrate chemical raw material drug.

Aluminum clofibrate is an antilipidemic agent used in various pharmaceutical products. The approval allows the drug to be used and sold in domestic preparations, enriching the company's specialty raw material drug pipeline.

While not expected to significantly impact current operating performance, the company anticipates a positive influence on future earnings as it expands sales.